Analysis of Survival by Tumor Response

Overview

Journal J Clin Oncol

Specialty Oncology

Date 1983 Nov 1

PMID 6668489

Citations 361

Authors

J R ANDERSON

K C Cain

R D Gelber

Affiliations

Soon will be listed here.

Abstract

The common practice of comparing the survival of responders and nonresponders when reporting the results of cancer chemotherapy treatment is investigated. The usual method of comparing responders and nonresponders is biased in favor of responders, and these results are frequently misinterpreted as providing evidence that response prolongs survival, or that the treatment under study is effective. Two valid methods for comparing responders and nonresponders are discussed and recommendations are made concerning the analysis of survival by response. A comparison of survival by response category may be useful descriptively, but such a comparison should not be used for inference concerning treatment effectiveness.

Citing Articles

Long-term survival and durable recovery of heart failure in patients with triglyceride deposit cardiomyovasculopathy treated with tricaprin.

Hirano K, Okamura S, Sugimura K, Miyauchi H, Nakano Y, Nochioka K Nat Cardiovasc Res. 2025; .

PMID: 39948308 DOI: 10.1038/s44161-025-00611-7.

Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis.

Strouse J, Chan K, Baccile R, He G, Louden D, Giurcanu M Front Immunol. 2024; 15:1499478.

PMID: 39737191 PMC: 11682972. DOI: 10.3389/fimmu.2024.1499478.

Sensitive liquid biopsy monitoring correlates with outcome in the prospective international GPOH-DCOG high-risk neuroblastoma RT-qPCR validation study.

van Zogchel L, Decarolis B, van Wezel E, Zappeij-Kannegieter L, Gelineau N, Schumacher-Kuckelkorn R J Exp Clin Cancer Res. 2024; 43(1):331.

PMID: 39722049 PMC: 11670466. DOI: 10.1186/s13046-024-03261-y.

Baugh J, Veldhuijzen van Zanten S, Fiocco M, Colditz N, Hoffmann M, Janssens G Neurooncol Adv. 2024; 6(1):vdae155.

PMID: 39582811 PMC: 11582646. DOI: 10.1093/noajnl/vdae155.

Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer.

Bjerrum A, Henriksen A, Knoop A, Berg T, Tuxen I, Lassen U BJC Rep. 2024; 2(1):82.

PMID: 39516687 PMC: 11523986. DOI: 10.1038/s44276-024-00108-z.